August 24, 2018

Medtronic Neurovascular
Amnon Talmor
Principal Regulatory Affairs Specialist
9775 Toledo Way
Irvine, California 92618

Re: K181060
   Trade/Device Name: Solitaire 2™ and Solitaire™ Platinum Revascularization Devices
   Regulation Number: 21 CFR 882.5600
   Regulation Name: Neurovascular Mechanical Thrombectomy Device for Acute Ischemic Stroke Treatment
   Regulatory Class: Class II
   Product Code: POL, NRY
   Dated: May 31, 2018
   Received: June 1, 2018

Dear Amnon Talmor:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Xiaolin Zheng -S

for Carlos L. Peña, PhD, MS
Director
Division of Neurological and Physical Medicine Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
Indications for Use

510(k) Number (if known)
K181060

Device Name
Solitaire™ 2 and Solitaire™ Platinum Revascularization Devices

Indications for Use (Describe)
1. The Solitaire™ 2 and Solitaire™ Platinum Revascularization Devices is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA). Endovascular therapy with the device should be started within 6 hours of symptom onset.

2. The Solitaire™ 2 and Solitaire™ Platinum Revascularization Devices is indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment.

Type of Use (Select one or both, as applicable)

- Prescription Use (Part 21 CFR 801 Subpart D)
- Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

- Department of Health and Human Services
- Food and Drug Administration
- Office of Chief Information Officer
- Paperwork Reduction Act (PRA) Staff
- PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
510(K) Summary - K181060

510(k) Owner: Medtronic Neurovascular
9775 Toledo Way
Irvine, CA 92618
Establishment Registration No. 2029214

Contact Person: Amnon Talmor
Principal Specialist, Regulatory Affairs
Telephone: (949) 297-9270
E-mail: amnon.talmor@medtronic.com

Date Summary Prepared: August 10, 2018

Trade Name of Device: Solitaire™ 2 and Solitaire™ Platinum Revascularization Devices

Common Name of Device: Neurovascular Mechanical Thrombectomy Device for Acute Ischemic Stroke Treatment; Catheter, thrombus retriever

Classification of Device: 21 CFR 882.5600 and 21 CFR 870.1250, Class II

Product Code: POL, NRY

Primary Predicate Devices: Solitaire™ 2 Revascularization Device K162539

Additional Predicate Devices: Solitaire™ Platinum Devices (K153071, K160641 and K161879)

Device Description:
The Solitaire™ 2 and Solitaire™ Platinum Revascularization Devices is designed to restore blood flow in patients experiencing ischemic stroke due to large intracranial vessel occlusion in the neurovasculature such as the internal carotid artery (ICA), M1 and M2 segments of the middle cerebral artery, basilar and the vertebral arteries. The distal nitinol portion of the subject device facilitates clot retrieval and has Platinum/Iridium radiopaque markers on the proximal and distal ends and, for some SKUs, at several locations along the body of the stent. The devices are supplied sterile and are intended for single-use only.
The purpose of this submission is a labeling change to include an alternative aspiration source in addition to the 60 cc syringe when using the Solitaire™ 2 and Solitaire™ Platinum Revascularization Devices.

The **indications for use** for the subject device are as follows:

1. The Solitaire™ 2 and Solitaire™ Platinum Revascularization Devices is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA). Endovascular therapy with the device should be started within 6 hours of symptom onset.

2. The Solitaire™ 2 and Solitaire™ Platinum Revascularization Devices is indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment.

**Device Comparison:**

Table 1 below provides a comparison between the subject, the primary predicate and additional predicate devices. All aspects of the design—including stent sizes, marker spacing, device and packaging materials, sterilization methods and how supplied—remain the same.
## Table 1: Comparison between the proposed Solitaire™ 2 and Solitaire ™ Platinum Revascularization Devices used with the alternative aspiration source to the primary predicate and additional predicate Solitaire™ 2 and Solitaire ™ Platinum Revascularization Devices

<table>
<thead>
<tr>
<th></th>
<th>Primary Predicate: Solitaire™ 2 Revascularization Device with syringe aspiration (K162539)</th>
<th>Additional Predicate devices (Solitaire™ Platinum Revascularization Device)</th>
<th>Subject: Solitaire™ 2 and Solitaire ™ Platinum Revascularization Devices used with Riptide™ Aspiration System</th>
<th>Rationale for Difference (if applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product code</td>
<td>POL and NRY</td>
<td>NRY</td>
<td>Same as primary predicate (K162539)</td>
<td>N/A</td>
</tr>
<tr>
<td>Indication for Use</td>
<td>The Solitaire™ 2 Revascularization Device is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA). Endovascular therapy with the device should be started within 6 hours of symptom onset. The Solitaire™ Revascularization Device is indicated to restore</td>
<td>The Solitaire™ Platinum Revascularization Device is indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment.</td>
<td>Same as primary predicate (K162539)</td>
<td>N/A</td>
</tr>
<tr>
<td>Primary Predicate:</td>
<td>Additional Predicate devices</td>
<td>Subject:</td>
<td>Rationale for Difference (if applicable)</td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------------------------</td>
<td>----------</td>
<td>-----------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Solitaire™ 2 Revascularization Device with syringe aspiration (K162539)</td>
<td>(Solitaire™ Platinum Revascularization Device)</td>
<td>Solitaire™ 2 and Solitaire™ Platinum Revascularization Devices used with Riptide™ Aspiration System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>K153071</td>
<td>K161879</td>
<td>K160641</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Principle of operation</strong></td>
<td></td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment.</td>
<td>The device is used in the neurovasculature to restore blood flow for treatment of acute ischemic stroke. The device is used in the neurovasculature to restore blood flow by removing thrombus</td>
<td>Same as primary predicate (K162539)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Procedural steps aspiration source</strong></td>
<td>Syringe</td>
<td>Aspiration Device</td>
<td>Bench testing and a review of relevant clinical literature demonstrates the alternative aspiration source does not raise any</td>
<td></td>
</tr>
</tbody>
</table>
### Table 1: Comparison between the proposed Solitaire™ 2 and Solitaire™ Platinum Revascularization Devices used with the alternative aspiration source to the primary predicate and additional predicate Solitaire™ 2 and Solitaire™ Platinum Revascularization Devices

<table>
<thead>
<tr>
<th>Device sizes (mm)</th>
<th>Primary Predicate: Solitaire™ 2 Revascularization Device with syringe aspiration (K162539)</th>
<th>Additional Predicate devices (Solitaire™ Platinum Revascularization Device)</th>
<th>Subject: Solitaire™ 2 and Solitaire™ Platinum Revascularization Devices used with Riptide™ Aspiration System</th>
<th>Rationale for Difference (if applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4x15 4x20 4x40 6x20 6x30</td>
<td>4x20 4x40 6x20 4x20x05 6x24x06 6x40x10</td>
<td>4x15 4x20 4x40 6x20 6x30 4x20x05 6x24x06 6x40x10</td>
<td>new issues of safety or effectiveness.</td>
</tr>
<tr>
<td>How supplied</td>
<td>Stored within dispenser coil, Tyvek pouch and shipping carton</td>
<td>N/A</td>
<td>N/A</td>
<td>The subject device scope includes the primary predicate and additional predicate devices. The sizes used in the simulated clot retrieval testing were identical to the primary predicate device and representative of the additional predicate devices.</td>
</tr>
</tbody>
</table>

| Sterilization method | Ethylene oxide       | N/A                                           | N/A                                           |

<table>
<thead>
<tr>
<th>Device materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stent</td>
</tr>
<tr>
<td>Push wire</td>
</tr>
<tr>
<td>Radiopaque markers</td>
</tr>
<tr>
<td>Push-wire shrink Tubing</td>
</tr>
<tr>
<td>Primary Predicate: Solitaire™ 2 Revascularization Device with syringe aspiration (K162539)</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>Introducer Sheath</td>
</tr>
<tr>
<td>Shrink tubing</td>
</tr>
</tbody>
</table>
**Performance Data**

Medtronic Neurovascular performed the following non-clinical bench tests to support the use of the alternative aspiration source with the Solitaire™ 2 and Solitaire™ Platinum Revascularization Devices:

<table>
<thead>
<tr>
<th>Test</th>
<th>Test Method Summary</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vacuum pressure testing</td>
<td>Purpose: Compare the ability of the alternative aspiration device to deliver vacuum pressure to the distal tip of the catheter to a 60 cc syringe. Method: The vacuum pressure was measured at the distal tip of the aspiration catheter when generated from the alternative aspiration device at various vacuum pressure settings, as well as from a 60 cc VacLok® Syringe.</td>
<td>Vacuum pressure delivered to the distal tip of the catheter from a 60 cc syringe exceeded the pressure delivered from the alternative aspiration device.</td>
</tr>
<tr>
<td>Simulated clot retrieval testing</td>
<td>Purpose: Compare the clot retrieval performance of the subject device when used with the alternative aspiration source to the cleared device use with a 60 cc syringe.</td>
<td>Clot retrieval performance of the subject device was equivalent to the predicate performance.</td>
</tr>
</tbody>
</table>

In addition to the above tests, Medtronic Neurovascular conducted a comprehensive review of relevant clinical literature to assess whether any issues of safety or effectiveness were raised by the clinical use of the alternative aspiration source with the Solitaire™ 2 and Solitaire™ Platinum Revascularization Devices.

**Conclusion**

Non-clinical bench testing and a review of relevant literature demonstrate the subject device is substantially equivalent to the predicate Solitaire™ 2 and Solitaire™ Platinum Revascularization Devices and does not raise any new questions of safety and effectiveness.